ESPE Abstracts

Introduction: GLP-1 receptor agonists (GLP1A) have been shown to be effective in achieving weight loss in adolescents with obesity and improve glycaemic control in type 2 diabetes mellitus (T2DM). We aimed to investigate the glycaemic alterations and satiety levels in patients treated with the GLP1A, liraglutide. To the best of our knowledge, this is the first study of its kind.

Methods: In total, 22 patients managed in a tier-3 multidisciplinary weight management service completed 3-months of liraglutide treatment in addition to lifestyle modification (mean dose: 2.4mg; range 1.2-3). Continuous glucose monitoring (CGM) was undertaken at baseline and at 3-months for 15 patients. PedsQL 4.0 Generic Core Scales and three-factor eating (TFEQ-R18) questionnaires to assess quality of life (QoL) and hunger, respectively, were completed.

Results: The mean age was 14.46 years (range: 12-16.7) and 63.6% (14/22) were female. A significant reduction in weight (-2.94kg; 95%CI 1.4-4.74; P<0.05), BMI (-1.44kg/m²; 95%CI 0.68-2.21; P<0.05), BMI SDS (-0.10; 95%CI 0.04-0.16; P<0.05) and body fat percentage was observed [Table 1]. CGM revealed improvements in the mean glucose levels and the percentage time in range increased from 77.96% to 87.16%. The percentage time above 10mmol/L reduced from 5.26% to 1.86%. Both child and parent reported QoL were shown to increase. The TFEQ-R18 showed an improvement in cognitive restraint, emotional eating and uncontrolled eating, with the latter being statistically significant (-9.79; 95% CI 2.37-17.20; P<0.05) [Table 1].

Conclusion:The results from our study show for the first time that GLP1A therapy improves glycaemic status and satiety levels, along with improvements in anthropometric measurements and QoL in CYP with obesity. The improvement in glycaemic dysregulation is promising and demonstrates the potential to prevent long-term glucose complications including the development of T2DM.